Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.